https://charts.traderzeitung.de/phases/US50015M1099
string(1438) "{"isin":"US50015M1099","name":"Kodiak Sciences Inc","stock_id_xnas":7874235,"stock_id_xnys":null,"generated_at":"2026-07-18 03:32:00","days":[{"date":"2026-07-15","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":43.41,"close_at":"2026-07-15 15:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":42.36,"close_at":"2026-07-15 21:59:00","complete":true,"perf_pct":-2.4188},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-16","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":41.69,"close_at":"2026-07-16 15:28:00","complete":true,"perf_pct":-1.5817},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":41.32,"close_at":"2026-07-16 21:59:00","complete":true,"perf_pct":-0.8875},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-17","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":42.64,"close_at":"2026-07-17 21:59:00","complete":true,"perf_pct":3.1946},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Kodiak Sciences Aktie News & Nachrichten

Kodiak Sciences Aktie News & Nachrichten

[WKN: A2N6P0 | Symbol: KOD]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Kodiak Sciences Chart

Pivotal-Point Nachverfolgung Kodiak Sciences (KOD): Phase-3-Erfolg markiert Wendepunkt in der Netzhauttherapie!

Kodiak Sciences fokussiert sich auf die Entwicklung neuartiger Therapeutika zur Behandlung schwerwiegender...

Kodiak Sciences (KOD) im Pivotal-Point-Check: Durchbruch in Phase-3-Studie für Augenheilkunde – Biotech-Aktie explodiert um über 70 %!

Positive GLOW2-Studienergebnisse: Zenkuda (Tarcocimab Tedromer) überzeugt mit hoher Wirksamkeit bei...

TOP-5-Kursziele der Analysten am 27.03.26

PVA TePla [DE0007461006] Deutsche Bank bestätigt Buy-Rating und erhöht das Kursziel von 33 auf 45...

Kodiak Sciences: Die Revolution der Augenheilkunde?

Kodiak Sciences ist ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das neuartige...

Kodiak Sciences im Fokus nach Hochstufung durch J.P. Morgan!

Kodiak Sciences ist ein biopharmazeutisches Unternehmen aus Palo Alto, Kalifornien, das sich auf die...

  • 1